Observational studyInternational journal of immunopathology and pharmacology2017

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.

Clementina Canessa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.